Citation tools
"Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2–positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib." Molecular Cancer Therapeutics
8.8
(2009):
2131-2141.
Web. 17 Jan. 2021.